Background: Previous studies suggest that recombinant thrombopoietin (rTPO) will increase platelet production in thrombocytopenic neonates. However, the target populations of neonates most likely to benefit should be defined. Studies suggest that rTPO will not elevate the platelet count until 5 days after the start of treatment. Therefore, the neonates who might benefit from rTPO are those who will require multiple platelet transfusions for more than 5 days. This study was designed to find means of prospectively identifying these patients.
Study Design And Methods: A historic cohort study of all patients in the neonatal intensive care unit (NICU) at the University of Florida who received platelet transfusions from January 1, 1997, through December 31, 1998, was conducted.
Results: Of the 1389 patients admitted to the NICU during the study period, 131 (9.4%) received platelet transfusions. Seventeen were treated with extracorporeal membrane oxygenation and were excluded from further analysis. Of the remaining 114 patients, 55 (48%) received one transfusion and 59 (52%) received more than one transfusion (21 had >4). None of the demographic factors examined predicted multiple platelet transfusions. However, two clinical conditions did; liver disease and renal insufficiency. Neonates who received one platelet transfusion had a relative risk of death 10.4 times that in neonates who received none (p = 0.0001). Neonates who received >4 platelet transfusions had a risk of death 29.9 times that in those who received no transfusions (p = 0.0001).
Conclusion: NICU patients with liver disease or renal insufficiency who receive one platelet transfusion are likely to receive additional transfusions. Therefore, these patients constitute a possible study population for a Phase I/II rTPO trial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1537-2995.2001.41060803.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early Thrombocytopenia at Hospital Admission Predicts Mortality in Patients with Non-Isolated Severe Traumatic Brain Injury.
Biomedicines
November 2024
Department of Anesthesiology and Critical Care, Gregorio Marañón Universitary General Hospital, 28007 Madrid, Spain.
Unlabelled: Patients with severe traumatic brain injury (STBI) often experience an abnormal hemostasis that contributes to mortality and unfavorable neurological outcomes.
Objectives: We aimed to analyze epidemiologic, clinical, and laboratory factors associated with mortality in patients with STBI during the first 48 h after in-hospital admission.
Methods: We performed an observational retrospective study of STBI patients with associated extracranial trauma [defined as Injury Severity Score (ISS) ≥ 16 with an Abbreviated Injury Scale (AIS) head and neck ≥ 3 and Glasgow Coma Scale (GCS) ≤ 8] admitted to a Level II trauma center over seven years (2015-2021).
Development of a simplified platelet cryopreservation method: An in vitro investigation of reducing the DMSO concentration to allow administration without its pre-transfusion removal.
Vox Sang
January 2025
Research and Development, Australian Red Cross Lifeblood, Alexandria, New South Wales, Australia.
Background And Objectives: The most widely used method of platelet cryopreservation requires the addition of 5%-6% dimethylsulphoxide (DMSO), followed by its pre-freeze removal via centrifugation, to minimize toxicity. However, this adds complexity to the pre-freeze and post-thaw processing. Accordingly, the aim of this study was to simplify platelet cryopreservation by reducing the DMSO concentration and omitting the requirement for pre-transfusion removal.
View Article and Find Full Text PDFEfficacy of eribulin monotherapy for bone marrow carcinomatosis of breast cancer in a patient with Werner syndrome.
Geriatr Gerontol Int
January 2025
Department of Medical Oncology, Sapporo Medical University, Sapporo, Japan.
Various complications and potential risks of serious adverse events lessens the intensity of chemotherapy in patients with Werner syndrome. Bone marrow carcinomatosis of breast cancer was developed in a patient with Werner syndrome. Eribulin proved well tolerated and effective in improving severe thrombocytopenia, leading to platelet transfusion-free status.
View Article and Find Full Text PDFDevelopment of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection.
Hepatol Int
January 2025
Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China.
Article Synopsis
- The study focused on evaluating the outcomes of liver resection in patients with large hepatocellular carcinoma (HCC), emphasizing the challenge of surgical treatment and the poor prognosis associated with this condition.
- Researchers analyzed data from 1710 large HCC patients to create predictive models for surgical risk, overall survival, and recurrence-free survival using regression analysis in both training and validation cohorts.
- Key factors identified included platelet count, tumor characteristics, and liver function metrics, and the models demonstrated good predictive capability, with C-index values ranging from 0.675 to 0.773, indicating their effectiveness in forecasting patient outcomes post-surgery.
[Autologous Stem-Cell Transplantation without Transfusion Support in Jehovah's Witness Patients. A case series].
Rev Med Chil
June 2024
Servicio de Medicina física y Rehabilitación, Hospital del Salvador, Santiago, Chile.
Article Synopsis
- Autologous Stem-Cell Transplantation (ASTC) is effective for treating certain blood cancers but can cause severe side effects due to intense chemotherapy.
- The study presents a protocol for performing ASTC without transfusions, catering to patients who decline blood products, such as Jehovah's Witnesses (JW).
- In a small trial with four patients (two with multiple myeloma and two with lymphomas), no serious complications occurred, and all patients remained alive and well at the time of reporting, showcasing the viability of the transfusion-free approach.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!